Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior ...
Orca-T with reduced-intensity stem cell transplantation was a safe, feasible alternative to conventional transplant in blood ...
Otsuka has dumped a clutch of clinical cancer candidates on Valentine's day. | Otsuka has broken up with a clutch of clinical ...
citing the organization’s failure to submit required clinical trial results to ClinicalTrials.gov. The notice reflects FDA’s increasing attention toward noncompliance with the agency’s ...
16don MSN
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry. The Danish drugmaker last month revealed disappointing ...
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, according to a entry. This study is not the new trial ...
Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial isanticipated in 1Q25 –– Presented Phase 1b data from the TACTIVE-U ...
Quality of life, treatment impact and duration, and the importance of individualized therapy are at the center of ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.
Completion of SON-1010 (IL12-FHAB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of ...
Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback